Multiple Sclerosis Journal - October 2017 - 1545
LE van den Akker, H Beckerman et al.
participation are also reported. The patients' treatment
adherence was determined by assessing the number of
sessions each participant attended.
Power analysis
The sample size calculation was based on a clinically
relevant between-group difference of ⩾8 points on
the CIS20r fatigue scale.22 In total, 90 patients (45 per
treatment group) were needed to detect this clinically
relevant difference with an standard deviation (SD) of
12.7,23 a power of 80%, an alpha of 0.05, and a maximum attrition rate of 20%.
Statistical analysis
Statistical analyses were pre-specified and performed
with SPSS for Windows statistical software package
(Version 22; SPSS, Inc., Chicago, IL). Primary analyses were performed according to the intention-to-treat
principle and consisted of all participants (analyzed as
randomized).
We used mixed linear models to study the effectiveness of CBT. Mixed-model analysis takes into account
the dependency of the repeated observations within
the patient. In total, three models were analyzed: (1) a
crude model, only adjusted for the baseline value of
the particular outcome; (2) a model adjusted for
center; scores of patients who belong to the same
center are correlated,23 therefore randomization was
stratified per center; (3) a model adjusted for covariates that were likely to have a prognostic influence to
improve precision.24 The covariates were determined
a priori: gender, disease severity (EDSS), general
self-efficacy (General Self-Efficacy Scale (GSES)),
anxiety (HADS, subscale anxiety), and comorbidities
(Cumulative Illness Rating Scale (CIRS)) at baseline.
For all models, both an overall effect of CBT and the
effects of CBT at the different measurement points
were estimated. For the latter, time and interaction
between group and time were added to the model.
Time was thereby treated as a categorical variable
represented by dummy variables.
Furthermore, we calculated the absolute risk reduction (ARR), the number needed to treat (NNT), and
the 95% confidence interval (CI) for patients who
showed an improvement of ⩾8 points on the CIS20r
fatigue scale and for patients who scored <35 on the
post-treatment measurement (T16). The NNT is the
average number of patients who need to be treated for
one patient to benefit in comparison to the control
group (in this case an improvement of ⩾8 points or a
score <35 points).25
journals.sagepub.com/home/msj
Results
Participants
The flow chart is displayed in Figure 1. Between
November 2011 and July 2014, 91 patients were randomized, of whom 44 were allocated to CBT and 47
to the MS nurse. Baseline demographic and disease
characteristics are displayed in Table 1.
Three patients (7%) in the CBT study group and eight
(17%) in the control study group dropped out during
the study. In total, 28 (64%) patients in the CBT study
group completed ⩾10 sessions, with a median of 10.5
sessions (interquartile (ICQ1-3): 8.8-11.0). In the control study group, 37 (79%) completed all three MS
nurse consultations, with a median 3 of sessions
(ICQ1-3: 3-3). The demographics of the drop-outs are
available in Supplementary Appendix 3.
During the treatment period, one serious adverse
event (MS relapse confirmed by a neurologist, followed by inpatient treatment) was reported in the
CBT study group, and two (one MS relapse and one
gall bladder surgery) were reported in the control
study group. During the long-term follow-up period,
three serious adverse events (two MS relapses and
one surgery) were reported in the CBT study group
and one (MS relapse) was reported in the control
study group. These events were reported to and judged
by the Medical Ethics Committee not to be directly
associated with the interventions.
Effect on fatigue and societal participation
The mean scores (SD) of the fatigue and participation
outcomes at baseline and follow-up are presented in
Table 2.
The between-group effects of the second model (i.e.
adjusted for center) of CBT on fatigue, societal participation, and secondary fatigue outcomes are displayed in Table 3. The results of the other models are
provided in Supplementary Appendix 4.
Post-treatment CIS20r fatigue scores showed a positive treatment effect for CBT compared to the MS
nurse intervention (β = −6.7 (95% CI = −10.7; −2.7))
(Figure 2) that gradually wore off during the subsequent 8 months (T52: β = 0.5 (95% CI = −3.5; 4.5)).
IPA domain scores did not show between-group differences at any time point, except for a significant
between-group effect on the IPA work and education
domain at T26 (β = −0.3 (95% CI = −0.7; −0.0)). In
addition to the CIS20r fatigue results, the secondary
fatigue measures showed comparable scoring patterns
1545
https://journals.sagepub.com/home/msj
Table of Contents for the Digital Edition of Multiple Sclerosis Journal - October 2017
Contents
Multiple Sclerosis Journal - October 2017 - Cover1
Multiple Sclerosis Journal - October 2017 - Cover2
Multiple Sclerosis Journal - October 2017 - Contents
Multiple Sclerosis Journal - October 2017 - ii
Multiple Sclerosis Journal - October 2017 - iii
Multiple Sclerosis Journal - October 2017 - 1436
Multiple Sclerosis Journal - October 2017 - 1437
Multiple Sclerosis Journal - October 2017 - 1438
Multiple Sclerosis Journal - October 2017 - 1439
Multiple Sclerosis Journal - October 2017 - 1440
Multiple Sclerosis Journal - October 2017 - 1441
Multiple Sclerosis Journal - October 2017 - 1442
Multiple Sclerosis Journal - October 2017 - 1443
Multiple Sclerosis Journal - October 2017 - 1444
Multiple Sclerosis Journal - October 2017 - 1445
Multiple Sclerosis Journal - October 2017 - 1446
Multiple Sclerosis Journal - October 2017 - 1447
Multiple Sclerosis Journal - October 2017 - 1448
Multiple Sclerosis Journal - October 2017 - 1449
Multiple Sclerosis Journal - October 2017 - 1450
Multiple Sclerosis Journal - October 2017 - 1451
Multiple Sclerosis Journal - October 2017 - 1452
Multiple Sclerosis Journal - October 2017 - 1453
Multiple Sclerosis Journal - October 2017 - 1454
Multiple Sclerosis Journal - October 2017 - 1455
Multiple Sclerosis Journal - October 2017 - 1456
Multiple Sclerosis Journal - October 2017 - 1457
Multiple Sclerosis Journal - October 2017 - 1458
Multiple Sclerosis Journal - October 2017 - 1459
Multiple Sclerosis Journal - October 2017 - 1460
Multiple Sclerosis Journal - October 2017 - 1461
Multiple Sclerosis Journal - October 2017 - 1462
Multiple Sclerosis Journal - October 2017 - 1463
Multiple Sclerosis Journal - October 2017 - 1464
Multiple Sclerosis Journal - October 2017 - 1465
Multiple Sclerosis Journal - October 2017 - 1466
Multiple Sclerosis Journal - October 2017 - 1467
Multiple Sclerosis Journal - October 2017 - 1468
Multiple Sclerosis Journal - October 2017 - 1469
Multiple Sclerosis Journal - October 2017 - 1470
Multiple Sclerosis Journal - October 2017 - 1471
Multiple Sclerosis Journal - October 2017 - 1472
Multiple Sclerosis Journal - October 2017 - 1473
Multiple Sclerosis Journal - October 2017 - 1474
Multiple Sclerosis Journal - October 2017 - 1475
Multiple Sclerosis Journal - October 2017 - 1476
Multiple Sclerosis Journal - October 2017 - 1477
Multiple Sclerosis Journal - October 2017 - 1478
Multiple Sclerosis Journal - October 2017 - 1479
Multiple Sclerosis Journal - October 2017 - 1480
Multiple Sclerosis Journal - October 2017 - 1481
Multiple Sclerosis Journal - October 2017 - 1482
Multiple Sclerosis Journal - October 2017 - 1483
Multiple Sclerosis Journal - October 2017 - 1484
Multiple Sclerosis Journal - October 2017 - 1485
Multiple Sclerosis Journal - October 2017 - 1486
Multiple Sclerosis Journal - October 2017 - 1487
Multiple Sclerosis Journal - October 2017 - 1488
Multiple Sclerosis Journal - October 2017 - 1489
Multiple Sclerosis Journal - October 2017 - 1490
Multiple Sclerosis Journal - October 2017 - 1491
Multiple Sclerosis Journal - October 2017 - 1492
Multiple Sclerosis Journal - October 2017 - 1493
Multiple Sclerosis Journal - October 2017 - 1494
Multiple Sclerosis Journal - October 2017 - 1495
Multiple Sclerosis Journal - October 2017 - 1496
Multiple Sclerosis Journal - October 2017 - 1497
Multiple Sclerosis Journal - October 2017 - 1498
Multiple Sclerosis Journal - October 2017 - 1499
Multiple Sclerosis Journal - October 2017 - 1500
Multiple Sclerosis Journal - October 2017 - 1501
Multiple Sclerosis Journal - October 2017 - 1502
Multiple Sclerosis Journal - October 2017 - 1503
Multiple Sclerosis Journal - October 2017 - 1504
Multiple Sclerosis Journal - October 2017 - 1505
Multiple Sclerosis Journal - October 2017 - 1506
Multiple Sclerosis Journal - October 2017 - 1507
Multiple Sclerosis Journal - October 2017 - 1508
Multiple Sclerosis Journal - October 2017 - 1509
Multiple Sclerosis Journal - October 2017 - 1510
Multiple Sclerosis Journal - October 2017 - 1511
Multiple Sclerosis Journal - October 2017 - 1512
Multiple Sclerosis Journal - October 2017 - 1513
Multiple Sclerosis Journal - October 2017 - 1514
Multiple Sclerosis Journal - October 2017 - 1515
Multiple Sclerosis Journal - October 2017 - 1516
Multiple Sclerosis Journal - October 2017 - 1517
Multiple Sclerosis Journal - October 2017 - 1518
Multiple Sclerosis Journal - October 2017 - 1519
Multiple Sclerosis Journal - October 2017 - 1520
Multiple Sclerosis Journal - October 2017 - 1521
Multiple Sclerosis Journal - October 2017 - 1522
Multiple Sclerosis Journal - October 2017 - 1523
Multiple Sclerosis Journal - October 2017 - 1524
Multiple Sclerosis Journal - October 2017 - 1525
Multiple Sclerosis Journal - October 2017 - 1526
Multiple Sclerosis Journal - October 2017 - 1527
Multiple Sclerosis Journal - October 2017 - 1528
Multiple Sclerosis Journal - October 2017 - 1529
Multiple Sclerosis Journal - October 2017 - 1530
Multiple Sclerosis Journal - October 2017 - 1531
Multiple Sclerosis Journal - October 2017 - 1532
Multiple Sclerosis Journal - October 2017 - 1533
Multiple Sclerosis Journal - October 2017 - 1534
Multiple Sclerosis Journal - October 2017 - 1535
Multiple Sclerosis Journal - October 2017 - 1536
Multiple Sclerosis Journal - October 2017 - 1537
Multiple Sclerosis Journal - October 2017 - 1538
Multiple Sclerosis Journal - October 2017 - 1539
Multiple Sclerosis Journal - October 2017 - 1540
Multiple Sclerosis Journal - October 2017 - 1541
Multiple Sclerosis Journal - October 2017 - 1542
Multiple Sclerosis Journal - October 2017 - 1543
Multiple Sclerosis Journal - October 2017 - 1544
Multiple Sclerosis Journal - October 2017 - 1545
Multiple Sclerosis Journal - October 2017 - 1546
Multiple Sclerosis Journal - October 2017 - 1547
Multiple Sclerosis Journal - October 2017 - 1548
Multiple Sclerosis Journal - October 2017 - 1549
Multiple Sclerosis Journal - October 2017 - 1550
Multiple Sclerosis Journal - October 2017 - 1551
Multiple Sclerosis Journal - October 2017 - 1552
Multiple Sclerosis Journal - October 2017 - 1553
Multiple Sclerosis Journal - October 2017 - 1554
Multiple Sclerosis Journal - October 2017 - 1555
Multiple Sclerosis Journal - October 2017 - 1556
Multiple Sclerosis Journal - October 2017 - 1557
Multiple Sclerosis Journal - October 2017 - 1558
Multiple Sclerosis Journal - October 2017 - 1559
Multiple Sclerosis Journal - October 2017 - 1560
Multiple Sclerosis Journal - October 2017 - 1561
Multiple Sclerosis Journal - October 2017 - 1562
Multiple Sclerosis Journal - October 2017 - 1563
Multiple Sclerosis Journal - October 2017 - 1564
Multiple Sclerosis Journal - October 2017 - 1565
Multiple Sclerosis Journal - October 2017 - 1566
Multiple Sclerosis Journal - October 2017 - Cover3
Multiple Sclerosis Journal - October 2017 - Cover4
https://www.nxtbookmedia.com